// App-Quantinova.ai

: Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Maria-Victoria Mateos

  • Francesca Marianatal Gay

  • Michel Delforge

  • Gordon Cook

  • Lucy DeCosta

  • Renaud Desgraz

  • Zsolt Szabo

  • Philippe Moreau

Medical Centers

  • Department of Hematology, Oncology and Immunology, University Hospital Tuebingen, Tuebingen, Germany

  • University Hospital of Salamanca, Salamanca, Spain

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Global Biostatistical Science, Amgen Ltd, Uxbridge, United Kingdom

  • Amgen (Europe) GmbH, Zug, Switzerland

  • Amgen (Europe) GmbH, Zug, Switzerland

  • University Hospital Hotel-Dieu, Nantes, France

Locations

  • Germany

  • Spain

  • Italy

  • Belgium

  • United Kingdom

  • Switzerland

  • France

Companies

  • Amgen (Europe) GmbH

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • carfilzomib Intravenous

  • ZoMaxx

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved